N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

ALK-Abelló A/S1,508 enrolled

Overview

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.

Condition: * persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication * HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.

Study Type

OBSERVATIONAL

Enrollment

1,508

Conditions

Allergic Rhinitis Due to House Dust Mite Allergic Asthma Due to Dermatophagoides Farinae Allergic Asthma Due to Dermatophagoides Pteronyssinus

Interventions

Tablet, DispersibleDRUG

1 tablet/day with 12 SQ-HDM per lyo-tablet

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent Exclusion Criteria: * Patient who did not have 12 months prior inclusion or have an on-going, House Dust Mite (HDM) Allergy Immunotherapy (AIT).

Locations (1)

Hôpital Arnaud de Villeneuve

Montpellier, France

Outcomes

Primary Outcomes

Safety analysis: Number of patients with at least one Adverse Event

Number of patients with at least one Adverse Events related to ACARIZAX®.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.